Skip to main content
NewslettersWatchlist

Abbvie Inc(ABBV-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low159.69
Day High163.05
Open:161.27
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Better Dividend Stock: AbbVie or Johnson & Johnson?
Motley Fool
3 Dividend Stocks to Buy and Hold for the Next Decade
Motley Fool
Why AbbVie Stock Stumbled Today Despite the Earnings Beat
Motley Fool
AbbVie (ABBV) Q1 2024 Earnings Call Transcript
Barchart
Stock Index Futures Climb on Upbeat Big Tech Earnings, U.S. Inflation Data Looms
Motley Fool
Buying the Dip in These 3 Undervalued Dividend Stocks
Barchart
Stocks Set to Open Higher as Investors Await Key U.S. Inflation Data and Big Tech Earnings
Motley Fool
Why I Keep Buying This Ultra-High-Yielding ETF for Passive Income
Baystreet
New Home Sales Due Next Week in Canada
Barchart
3 Defensive Stocks for 'Sell in May' Season
Motley Fool
Is AbbVie a Millionaire Maker?
Motley Fool
3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade
Motley Fool
3 No-Brainer Dividend Stocks to Buy in April
Barchart
Stocks Rise After Jobs Report Exceeds Forecasts
Barchart
Hawkish Fed Comments Knock Stocks Lower
Motley Fool
Got $3,000? 2 Monster Growth Stocks to Buy Right Now Without Hesitation
Motley Fool
Meet The "Magnificent Seven" of Healthcare Stocks
Motley Fool
3 Reliable Dividend Growth Stocks With Yields Above 3% That You Can Buy Now and Hold for at Least a Decade
Barchart
3 Passive Income Stocks To Scoop Up Now
Barchart
3 Highest Yielding Dividend Kings in March 2024
Motley Fool
2 Top Dividend Stocks to Buy Hand Over Fist
Motley Fool
How Much a $1 Million Portfolio Would Pay in Dividends
Motley Fool
3 Pharmaceutical Stocks to Buy Hand Over Fist in March
Motley Fool
The AI Race Gets Litigious
Motley Fool
Have $2,500? 2 Superior Growth Stocks to Buy in 2024
GlobeNewswire
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
Newswire.ca
Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303
Motley Fool
Better Dividend Growth Stock: AbbVie or Amgen?
Motley Fool
Is AbbVie Stock a Buy Now?
Barchart
4 Top Dividend Kings to Earn Passive Income
Barchart
The Best of the Best: The Top Dividend Aristocrats To Buy Now
Motley Fool
3 Magnificent Dividend Growth Stocks to Buy Now and Hold for at Least a Decade

Profile

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.